This is one of the first studies to attempt to determine the prevalence of pulmonary hypertension in a community setting. The target population was patients diagnosed with HFpEF and followed over 3 years. They determined that pulmonary hypertension highly prevalent (83%), indicating the urgent need for a broader scale effort to screen for pulmonary hypertension. In addition, they show that pulmonary hypertension was strongly associated with mortality, underscoring the unmet need for therapies.
This Canadian study includes a cohort of over 50,000 patients with pulmonary hypertension over a 10-year period. They confirm that the incidence and prevalence of pulmonary hypertension is increasing, with Group 2 and group 3 associated with the highest mortality.
© Copyright 2023 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design